Condition

Recurrent Mantle Cell Lymphoma clinical trials and research

• 11Clinical trials
• 1New in 30 days
• 1Country

Newest Recurrent Mantle Cell Lymphoma clinical trials

All recruiting trials (11)

• Natalizumab to help prevent brain-related side effects during CAR-T therapy in certain lymphoma patients

  This phase 2 study tests whether natalizumab can reduce severe ICANS in adults with recurrent or refractory DLBCL or MCL receiving CAR-T therapy.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07892027

• Intrathecal Cytarabine and Hydrocortisone to Treat ICANS in NHL Patients Receiving CAR-T

  This trial tests whether giving cytarabine and hydrocortisone into the spine early after CAR-T therapy can reduce brain-related side effects in adults with non-Hodgkin lymphoma.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07763210

• Nemtabrutinib Plus Brexucabtagene Autoleucel (Brexu-Cel) in Relapsed or Refractory Mantle Cell Lymphoma

  This phase 2 trial tests whether adding nemtabrutinib to brexu-cel can help people whose mantle cell lymphoma has come back or not responded to prior treatment.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07673367

• Golgadomide plus rituximab for relapsed or refractory mantle cell lymphoma

  This phase I/II trial tests whether golcadomide given with rituximab is safe and can help people with mantle cell lymphoma that has come back or stopped responding to treatment.

  Recruiting Phase 1/2 City of Hope Medical Center · Duarte, California · NCT07578077

• Glofitamab plus obinutuzumab for mantle cell lymphoma after CAR‑T

  This trial tests whether the antibody drug glofitamab given with obinutuzumab can shrink or control mantle cell lymphoma that returned or didn't respond after CD19 CAR‑T therapy in adults.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 10 other locations · NCT07003295

• Zanubrutinib plus sonrotoclax for relapsed or refractory B‑cell non‑Hodgkin lymphoma in underrepresented racial and ethnic groups

  This phase 1 trial tests whether combining zanubrutinib and sonrotoclax can help adults from underrepresented racial and ethnic groups whose B‑cell non‑Hodgkin lymphoma has returned or not responded to prior treatment.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06859008

• Combination treatment for chronic lymphocytic leukemia and lymphoma

  This study is testing a new combination treatment with sonrotoclax and either zanubrutinib or rituximab to see if it can help patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma.

  Recruiting Phase 2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06839053

• Pacritinib combined with a BTK inhibitor for relapsed or refractory mantle cell lymphoma

  This study tests whether adding pacritinib to a BTK inhibitor is safe and can help adults whose mantle cell lymphoma has returned or not responded to prior treatments.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06675123

• Treatment using modified T-cells for relapsed or refractory B-cell cancers

  This study is testing a new treatment that uses specially modified T-cells to see if it can help people with hard-to-treat B-cell cancers.

  Recruiting Phase 1 Mayo Clinic · Jacksonville, Florida · NCT06191887

• Combination treatment for relapsed or refractory mantle cell lymphoma

  This study is testing a new combination of three drugs to see if it can help people with relapsed or refractory mantle cell lymphoma feel better and live longer.

  Recruiting Phase 2 Academic and Community Cancer Research United · Rochester, Minnesota and 1 other locations · NCT05910801

• Using genetically modified T-cells and a vaccine to treat certain types of B-cell lymphoma after stem cell transplantation

  This study is testing a new treatment using specially modified immune cells and a vaccine to see if it can help people with certain types of B-cell lymphoma after they've had a stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT05432635

Related topics

Quick answers

How many Recurrent Mantle Cell Lymphoma clinical trials are recruiting right now?

11, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in United States. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 6, Phase 1: 4, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →